

SECURITIES CONSOLIDATION CLARIFICATION

MELBOURNE (AUSTRALIA) 16 October 2024: Invision Limited (ASX: IVX) (“**Invision**” or the “**Company**”) wishes to provide clarification that the Indicative Timetable pursuant to Resolution 7 ‘100:1 Consolidation of Capital of the Company’ in the Notice of Meeting lodged with the ASX on 15 October 2024 has now been updated and the Indicative Timetable is outlined below:

Event	Date
Company announces Consolidation by issuing an Appendix 3A.3 notice Notice of Meeting despatched	15 October 2024
Date of Meeting	14 November 2024
Effective date of Consolidation	18 November 2024
Last date for trading in pre-Consolidation Shares	19 November 2024
Unless otherwise determined by ASX, trading commences in the post-Consolidation Shares on a deferred settlement basis	20 November 2024
Record date Last day for Company to register transfers on a pre-Consolidation basis	21 November 2024
First day for Company to update register and send holding statements to Shareholders reflecting the change in the number of shares they hold	22 November 2024
Last day for Company to update its register and send holding statements to securityholders reflecting updated numbers and to notify ASX that this has occurred	28 November 2024

This announcement was approved for release by the Board of Directors.

Sign up at Invision’s Investor Hub to receive regular updates, provide feedback and participate in discussions: <https://investors.inviongroup.com/>

Investor and Media enquiries:

Thian Chew (Chairman & CEO)

Brendon Lau (Investor & Media Relations)

ASX ANNOUNCEMENT

T: +61 3 9692 7222

E: investor@inviongroup.com

M: +61 409 341 613

E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".